Anti-nausea agent beginning Phase III trials

OPKO Health Inc has announced it is launching a trio of Phase III clinical trials to evaluate how effective their drug Rolapitant® is in dealing with Chemotherapy-Induced Nausea and Vomiting (CINV).

Rolapitant is a Neurokinin-1 (NK-1) receptor antagonist being developed by OPKO and TESARO for patients receiving chemotherapy regimens that are typically known to induce nausea and vomiting to one degree or another.

The company will be running a pair of randomized, double-blind and placebo-controlled clinical trials evaluating the efficacy of a single 200mg oral dose of rolapitant in patients being given highly emetogenic chemotherapy, or HEC. Enrollment for each trial is expected to be around 530 patients, or over 1,000 in all.

The third trial will evaluate the efficacy of a single 200mg oral dose of rolapitant in patients receiving moderately emetogenic chemotherapy, or MEC. This trial will recruit 2,400 cancer patients.

Results are expected sometime in 2013. Currently, rolapitant is an investigational agent only, and not approved by the FDA or any other known regulatory agencies.

Source: Therapeutics Daily

More Articles

More Articles

This article looks at the Non-Hodgkin's Lymphoma survival rate as well as the Non-Hodgkin's Lymphoma mortality rate ....

The term NK T cell lymphoma refers to one of two subtypes of lymphoma that affect the NK (Natural Killer)...

Canine lymphoma is a fairly common cancer in American dogs. The most commonly seen lymphoma in America is a type called Lymphosarcoma, although...

Prednisone is a glucocorticosteroid (a steroid) used in the treatment of many types of cancers. It functions as an anti-inflammatory medicine that...

Marginal zone lymphomas (MZL) are indolent lymphomas that affect the B-cells. The...

Large Cell Lymphoma (LCL) is typically an aggressive (fast growing) cancer of either the B cell or T cell type. They are one of the most common...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A lymphoma prognosis varies greatly depending on the type of lymphoma. There are more than 35 types of lymphoma, including 5 types of...

What causes lymphoma is not well known. DNA mutations may be what causes lymphoma to develop but what triggers these mutations is...

Often the one who makes the first diagnosis of Hodgkin's Lymphoma / Disease is the person affected. There are some...

Lymphedema is abnormal swelling due to the presence of excess lymphatic fluid within the tissues. This swelling occurs when the...

RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE...

Hodgkin's Disease—also referred to as Hodgkin's Lymphoma, these are the exact same diseases, just...

Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. The cells begin to grow abnormally and much faster...